Is DCIS Breast Cancer, and How Do I Treat it?
- 1.1k Downloads
Ductal carcinoma in situ (DCIS) is a pre-invasive stage of breast cancer with a heterogeneous clinical behaviour. Since the introduction of mammographic screening programmes, the incidence of DCIS has shown a dramatic increase. Treatment should focus on the prevention of progression to invasive disease. If progression occurs, poorly differentiated DCIS frequently gives rise to grade III invasive breast cancer, whereas well differentiated DCIS more often recurs as grade I invasive disease. However, at present, validated diagnostic test are lacking to predict progression accurately. The majority of women with DCIS are suitable for breast conserving therapy. Obtaining clear surgical margins is the most important goal of a local excision. Radiotherapy is effective in reducing the risk of local recurrence with about 50 % in all subgroups of patients with DCIS. (Breast cancer specific) survival of women with DCIS is excellent, and radiotherapy does not further improve this. Future research should be directed in enabling to select women who have a high risk of—invasive—recurrence, so in which radiotherapy should be standard part of the breast conserving approach, and those women with a more indolent lesion, in which after surgery a watchful waiting approach can be followed.
KeywordsDuctal carcinoma in situ DCIS Breast cancer Breast conserving therapy Surgery radiotherapy Mammogram MRI
No potential conflicts of interest relevant to this article were reported.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Bloodgood JC. Comedo carcinoma (or comedo-adenoma) of the female breast. Am J Cancer. 1934;22:842–53.Google Scholar
- 2.MacCarty WC. Carcinoma of the breast. Transact South Surg Gynaecol Assoc. 1911;23:262–70.Google Scholar
- 11.Dutch Cancer Registry hosted by IKNL ©: Incidence breast cancer/DCIS, Available at http://cijfersoverkanker.nl. Accessed October 2012.
- 12.Bluekens AM, Holland R, Karssemeijer N, Broeders MJ, den Heeten GJ. Comparison of Digital Screening Mammography and Screen-Film Mammography in the Early Detection of Clinically Relevant Cancers: A Multicenter Study. Radiology. 2012 Oct 2. [Epub ahead of print] PubMed PMID: 23033499.Google Scholar
- 14.•Broeders M, Moss S, Nystromm L, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen. 2012;19:33–41.In this systematic review of observational studies investigating the impact of mammographic screening on breast cancer mortality, a European estimate of breast cancer mortality reduction of 38-48 % for screened women was found.PubMedCrossRefGoogle Scholar
- 22.Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol. 1994;11:208–14.PubMedGoogle Scholar
- 24.van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer N Engl J Med. 1988;319:1239–45.Google Scholar
- 27.Solin LJ. A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194 [abstract S4-6]. Presented at the 34th Annual San Antonio Breast Cancer Symposium 2011.Google Scholar
- 33.•Schouten van der Velden AP, Schlooz-Vries MS, Boetes C, Wobbes T. Magnetic resonance imaging of ductal carcinoma in situ: what is its clinical application? A review. Am J Surg. 2009;198:262–9. In this review, the value but also the limitations of the role of MRI for DCIS are highlighted.PubMedCrossRefGoogle Scholar
- 37.•Lovrics PJ, Goldsmith CH, Hodgson N, et al. A multicenter, randomized, controlled trial comparing radioguided seed localization to standard wire localization for nonpalpable, invasive and in situ breast carcinomas. Ann Surg Oncol. 2011;18:3407–14. A randomized, controlled trial comparing ROLL with wire localization for nonpalpable breast cancers shows that the ROLL procedure is shorter, with less ranked pain for the patients while the rate of complete excisions is similar in the two groups.PubMedCrossRefGoogle Scholar
- 38.Lovrics PJ, Cornacchi SD, Vora R et al. Systematic review of radioguided surgery for non-palpable breast cancer. Eur J Surg Oncol 2011.Google Scholar
- 40.Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853–a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–7.PubMedCrossRefGoogle Scholar
- 42.••Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–88. The NSABP B-17 is one of the randomized, clinical trials to investigate the role of radiotherapy in breast-conserving therapy for DCIS that published its results here with long-term follow-up of 207 months. It is a combined publication with the results of the NSABP B-24 trial, which analyzed the role of tamoxifen in BCT for DCIS.PubMedCrossRefGoogle Scholar
- 51.Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010;28:3929–36.PubMedCrossRefGoogle Scholar
- 55.•Grin A, Horne G, Ennis M, O'Malley FP. Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods. Arch Pathol Lab Med. 2009;133:31–7. This study shows that the serial sequential sampling method is the preferred method in accurately measuring extent of DCIS cases.PubMedGoogle Scholar
- 56.Chadha M, Portenoy J, Boolbol SK, et al. Is there a role for postmastectomy radiation therapy in ductal carcinoma in situ? Int J Surg Oncol. 2012;2012:423–520.Google Scholar
- 63.•Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:1615–20. A meta-analysis of randomized and nonrandomized clinical studies was performed to investigate the effect of margin status on the risk of recurrence in BCT with radiotherapy for DCIS. It was concluded that margins should be negative in BCT for DCIS. More specifically, a margin threshold of 2 mm seems to be as good as a larger margin width.PubMedCrossRefGoogle Scholar
- 66.Solin LJ, Fourquet A, Vicini FA, et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys. 2001;50:991–1002.PubMedCrossRefGoogle Scholar
- 67.••Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010:162–77. This paper presents the meta-analysis of randomized, clinical trials performed by the Early Breast Cancer Trialists’ Collaborative Group investigating the effect of radiotherapy on the risk of recurrence in breast-conserving therapy for DCIS.PubMedCrossRefGoogle Scholar
- 68.••Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:21–9. The long-term results of the U.K. DCIS trial are presented in this paper. At a median follow-up of 12.7 years, the beneficial effect of radiotherapy in BCT to reduce the risk of local recurrence is confirmed and is shown that tamoxifen reduces both the reduction of the risk of ipsilateral DCIS recurrence and contralateral breast cancer.PubMedCrossRefGoogle Scholar
- 70.Alvarado R, Lari SA, Roses RE et al.. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012.Google Scholar
- 73.•Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319–24. The ECOG 5194 trial is the largest prospective, nonrandomized trial in which 670 women with DCIS were treated with breast-conserving surgery without radiotherapy. It shows that small low- or intermediate-grade DCIS excised with wide tumor-free margins have a LR risk of 6.1 % at 5 years. High-grade lesions did much worse with a 5-year LR risk of 15.3 %.PubMedCrossRefGoogle Scholar
- 75.Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol. 2007;25:3259–65.PubMedCrossRefGoogle Scholar